King’s College London Confidence in Concept 2018
Lead Research Organisation:
King's College London
Department Name: UNLISTED
Abstract
King’s College London Confidence in Concept 2018
Technical Summary
King’s College London Confidence in Concept 2018
Organisations
- King's College London (Lead Research Organisation)
- Charité - University of Medicine Berlin (Collaboration)
- Viapath (Collaboration)
- King's College Hospital (Collaboration)
- Sheffield Children's Hospital (Collaboration)
- University of Chicago (Collaboration)
- National Jewish Medical and Research Center, USA (Collaboration)
- Southampton Hospital (Collaboration)
- Federal University of São Paulo (Collaboration)
- UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST (Collaboration)
- Benaroya Research Institute (Collaboration)
- Royal Manchester Children's Hospital (Collaboration)
- SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST (Collaboration)
- Danaher Corporation (Collaboration)
- University College Hospital (Collaboration)
- Murdoch Children's Research Institute (Collaboration)
- NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Stanford University (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Curie Institute Paris (Institut Curie) (Collaboration)
- University of Bonn (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
People |
ORCID iD |
Publications
Qian S
(2021)
An in-silico assessment of efficacy of two novel intra-cardiac electrode configurations versus traditional anti-tachycardia pacing therapy for terminating sustained ventricular tachycardia.
in Computers in biology and medicine
Santos AF
(2021)
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice.
in Allergy
Foong RX
(2021)
Biomarkers of diagnosis and resolution of food allergy.
in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Spiteri C
(2020)
Biomaterials-based approaches to model embryogenesis.
in Biomaterials science
Phillips BL
(2021)
Effect of delayed graft function on longer-term outcomes after kidney transplantation from donation after circulatory death donors in the United Kingdom: A national cohort study.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Shiu KY
(2020)
Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts.
in Frontiers in immunology
Bornstein SR
(2020)
Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation.
in Molecular psychiatry
Dassios T
(2022)
Functional morphometry to estimate the alveolar surface area using a premature baboon model.
in Journal of applied physiology (Bethesda, Md. : 1985)
Foong RX
(2021)
Improving Diagnostic Accuracy in Food Allergy.
in The journal of allergy and clinical immunology. In practice
Shapey J
(2021)
Integrated multi-modality image-guided navigation for neurosurgery: open-source software platform using state-of-the-art clinical hardware.
in International journal of computer assisted radiology and surgery
Chandak P
(2022)
Modelling acute antibody-mediated rejection of human kidney transplants using ex-vivo warm machine perfusion.
in EBioMedicine
Dassios T
(2022)
Multiprofessional cross-site working between a level 1 and a level 3 neonatal unit: a retrospective cohort study
in BMJ Paediatrics Open
Wilkinson H
(2021)
PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses.
in iScience
Maruszak A
(2023)
Predicting progression to Alzheimer's disease with human hippocampal progenitors exposed to serum
in Brain
Santos AF
(2021)
Prevention of food allergy: can we stop the rise of IgE mediated food allergies?
in Current opinion in allergy and clinical immunology
Chen D
(2020)
Regression of Atherosclerosis in ApoE-/- Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotopic" Anti-Thrombin Without Prolonged Anticoagulation.
in Journal of the American Heart Association
Walgrave H
(2021)
Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer's disease.
in Cell stem cell
De Lucia C
(2021)
Serum from Older Adults Increases Apoptosis and Molecular Aging Markers in Human Hippocampal Progenitor Cells.
in Aging and disease
Du Preez A
(2022)
The serum metabolome mediates the concert of diet, exercise, and neurogenesis, determining the risk for cognitive decline and dementia.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Peters RL
(2021)
Update on food allergy.
in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
| Description | EAACI Food Allergy Guidelines |
| Geographic Reach | Europe |
| Policy Influence Type | Membership of a guideline committee |
| Description | WHO IUIS Allergen Nomenclature Committee Member |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Data-driven composite biomarker development for the personalised management of vestibular schwannoma |
| Amount | £82,227 (GBP) |
| Organisation | MRC Doctoral Training Program |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2022 |
| End | 10/2025 |
| Description | ERA-HDHL Call for Joint Transnational Research Proposals: "Addressing adverse and beneficial effects of food ingredients and food processing on hypersensitivities to food" (FOOD_HYPERSENS) |
| Amount | £1,000,000 (GBP) |
| Funding ID | BB/X002519/1 |
| Organisation | King's College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2022 |
| End | 03/2025 |
| Description | Food Allergy Research and Education |
| Amount | $500,000 (USD) |
| Organisation | Food Allergy Research and Education (FARE) |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 04/2021 |
| End | 04/2024 |
| Description | King's College London Confidence in Concept 2018 |
| Amount | £1,000,000 (GBP) |
| Funding ID | MC_PC_18052 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 03/2021 |
| Description | MRC Transition Support CSF Alexandra Santos |
| Amount | £700,773 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 07/2022 |
| Description | Mast cell activation in the EAT and EAT-On Study |
| Amount | £10,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 03/2022 |
| Description | Novel Biomarkers: Ireland, Netherlands, UK program |
| Amount | £40,139,300 (GBP) |
| Funding ID | UB190099 |
| Organisation | W. Garfield Weston Foundation |
| Sector | Charity/Non Profit |
| Country | Canada |
| Start | 10/2020 |
| End | 10/2023 |
| Description | RLWT Program Grant 2020, Microbiome Brain Health and Aging |
| Amount | £709,165 (GBP) |
| Organisation | Reta Lila Weston Trust For Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 08/2024 |
| Title | Basophil activation test |
| Description | The whole blood basophil activation test is an in vitro assay where basophils in whole blood are stimulated with allergen and the expression of basophils' surface markers of activation are subsequently measured by flow cytometry. This assay was not previously performed in the host institution, was developed and optimised as part of the present research project and has proven to be very robust and to perform consistently. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | The basophil activation test (BAT) will be assessed as a tool for the diagnosis of food allergy and will be used in mechanistic experiments. BAT will be clinically validated and may be applied in the diagnosis of food allergy in clinical practice, reducing the need for oral food challenges and inherent costs and risks. BAT will also be used to unravel immunologic mechanisms of allergy versus tolerance, allowing us to understand why some children with IgE to foods react clinically whilst other children with equivalent levels of IgE do not. |
| Title | Predicting Allergic Reactions During Oral Peanut Challenges |
| Description | his prediction tool calculates the reaction severity based on a published model developed from the LEAP, LEAP-On, and PAS studies. This tool uses the basophil activation test (BAT), skin prick test (SPT) size (mm), and the level of Ara h 2-specific IgE (kU/L) to predict reaction severity defined as no reaction, moderate reaction, or a severe reaction. The values of these biomarkers are combined to give the predicted probabilities of falling into each of the severity categories. This tool may be useful for clinicians when assessing the risk of conducting oral food challenges to diagnose peanut allergy. All study details and modeling are outlined in "Santos AF, et al., Biomarkers of severity and threshold of allergic reactions during oral peanut challenges. J Allergy Clin Immunol. 2020 Aug;146(2):344-355. PMID: 32311390." |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | This tool has been useful for clinical teams to determine the likelihood of patients to react during peanut challenges. |
| URL | https://benaroyaresearch.shinyapps.io/peanutallergytool/ |
| Description | BAT to clinic |
| Organisation | Danaher Corporation |
| Department | Beckmann Coulter |
| Country | United States |
| Sector | Private |
| PI Contribution | We designed the study, the experiments, recruited the patients, generated and analysed the data and interpreted the results. We secured the fundings required to provide the necessary equipment and reagents for the project. |
| Collaborator Contribution | Viapath provided some time from their employees to support the project. Beckman Coulter provided the reagents for the trials runs before the start of the project. |
| Impact | Funding from the MRC Confidence in Concept Scheme through the KHP Challenge Fund. |
| Start Year | 2019 |
| Description | BAT to clinic |
| Organisation | Viapath |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We designed the study, the experiments, recruited the patients, generated and analysed the data and interpreted the results. We secured the fundings required to provide the necessary equipment and reagents for the project. |
| Collaborator Contribution | Viapath provided some time from their employees to support the project. Beckman Coulter provided the reagents for the trials runs before the start of the project. |
| Impact | Funding from the MRC Confidence in Concept Scheme through the KHP Challenge Fund. |
| Start Year | 2019 |
| Description | Basophil activation test in the TREAT study |
| Organisation | Murdoch Children's Research Institute |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | I have provided my expert advise and intellectual input in the design of experiments to assess basophil activation to tree nuts in children recruited into the Treeat Trial. |
| Collaborator Contribution | Treeat is an interventional randomised controlled study to find out if the introduction of multiple tree nuts in a hospital oral food challenge is better for prevention of tree nut allergy and is easier for families, than standard care. |
| Impact | None |
| Start Year | 2021 |
| Description | Basophil activation test to diagnose cow's milk allergy in Brazil |
| Organisation | Federal University of São Paulo |
| Country | Brazil |
| Sector | Academic/University |
| PI Contribution | I have provided expert advice on the study design and experimental set up of a study on the utility of the basophil activation test to diagnose cow's milk allergy in Sao Paulo. I have trained the PI of the study on the basophil activation test in my lab during a Sabbatical visit in 2020. |
| Collaborator Contribution | My collaborator is setting up and leading the study in Brazil. |
| Impact | Not yet. |
| Start Year | 2020 |
| Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
| Organisation | Charité - University of Medicine Berlin |
| Department | Paediatric Endocrinology Charité |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
| Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
| Impact | Not yet |
| Start Year | 2021 |
| Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
| Organisation | Curie Institute Paris (Institut Curie) |
| Department | BioPhenics Platform |
| Country | France |
| Sector | Public |
| PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
| Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
| Impact | Not yet |
| Start Year | 2021 |
| Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
| Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
| Impact | Not yet |
| Start Year | 2021 |
| Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
| Organisation | University of Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
| Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
| Impact | Not yet |
| Start Year | 2021 |
| Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
| Organisation | Benaroya Research Institute |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
| Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
| Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
| Start Year | 2020 |
| Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
| Organisation | National Jewish Medical and Research Center, USA |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
| Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
| Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
| Start Year | 2020 |
| Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
| Organisation | Stanford University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
| Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
| Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
| Start Year | 2020 |
| Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
| Organisation | University of Chicago |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
| Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
| Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | Addenbrooke's Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | King's College Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | Royal Manchester Children's Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | Sandwell and West Birmingham Hospitals NHS Trust |
| Department | Rheumatology Sandwell and West Birmingham |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | Sheffield Children's Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | Southampton Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | University College Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | University Hospitals of Leicester NHS Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
| Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Title | COMPOSITIONS AND METHODS |
| Description | The invention relates to a compound comprising: CH2-CH2-F-Cha-Cha-RKPNDK-NH2 joined via a linking group to [Myr2]-KSSKSPSKKDDKKPGD. The invention also relates to its use in treatment of atheroma, use in treatment of atherosclerosis, use in inducing regression of atherosclerosis, and use in treatment of Acute Kidney Injury (AKI). |
| IP Reference | WO2021171025 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | N/A |
| Title | DEVICES AND METHODS FOR THE DETECTION OF INTRAORAL ACID EXPOSURE |
| Description | The present invention provides non-invasive intraoral devices and methods for the detection of intraoral acid exposure, methods of making said devices, and their use in the diagnosis of disorders such as gastro-oesophageal reflux disease (GORD). |
| IP Reference | WO2021048396 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | N/A |
| Title | LITHIATED SILICON |
| Description | Lithiated porous silicon particles comprising lithium, silicon and oxygen, a method of making the particles, and uses of the particles are described. |
| IP Reference | WO2022029277 |
| Protection | Patent application published |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | n/a |
| Title | Basophil activation test to peanut |
| Description | The laboratory technique has been developed and validated for peanut allergy using samples from study ID 10020 in CRN Portfolio. Diagnostic performance and cut-off values have been determined and validated. It is currently being tested and validated to diagnose other food allergies, incluing milk, egg, sesame and cashew nut allergies. I would like to translate it to a clinical laboratory with the view of applying it to clinical practice. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | CRN Portfolio 10020 |
| Impact | This test will improve the accuracy of the diagnosis of peanut allergy and reduce the number of oral food challenges to peanut. |
| URL | https://clinicaltrials.gov/show/NCT03309488 |
| Title | 7 Tesla MRI flexible body coil with 10 transmit dipoles and 30 receive loops |
| Description | The lack of body coil at 7 Tesla brings the need for dedicated transmit coils for each body area. However, due to the short wavelength at Ultra High Field , implementation of a large body coil is challenging and thus the use of volume coils such as birdcage is not practical beyond the head area. Transmit arrays consisting of loops are proposed with the use of radio frequency (RF) shimming to target areas for imaging. However, the penetration is inadequate when the region of interest (ROI) is deeper in the human body, such as the prostate. Transmit dipoles overcome this problem since they can operate in the far field even when positioned near the skin, and they provide adequate coverage in deeper organs with RF shimming. Thus, a 10 dipole transmit array was designed and implemented along with a 30 loop receive array. The areas of interest targeted in this study were prostate, hip and kidney imaging. |
| Type Of Technology | Detection Devices |
| Year Produced | 2021 |
| Impact | A novel coil design is proposed holding both transmit dipoles and receive array in one flexible assembly. Other flexible coil assemblies so far would have separate parts for the Tx and Rx arrays but this one incorporates both at the same time. Thus, superior coverage is achieved, and dipole loading is better controlled since the distance from the skin is fixed considering that the flexible coil follows the body curve. First results work as a proof of principle that the two arrays can work in such proximity. Challenges were overcome with various RF measures such as use of multiple floating BALUNs for cable arrangement. Results were comparable to a commercial coil which had smaller B1 coverage and one loop array operating as a transceiver. |
| URL | https://archive.ismrm.org/2022/2255.html |
| Description | Allergy UK Masterclass 2019 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The patient organisation and Charity Allergy UK organised a one-day event targeting health care professionals and patient groups. Experts in different aspects of allergic diseases shared their knowledge and expertise and answered questions. |
| Year(s) Of Engagement Activity | 2019 |
| Description | BBC Radio 4 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | BBC radio 4 interview exploring the role of neurogenesis and its modulation via diet and exercise- upon publication of our article: https://www.nature.com/articles/s42003-020-0844-1 |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.bbc.co.uk/programmes/m000kfqy |
| Description | FARE Research Retreat for patients and public |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | • FARE Research Retreat for patients - lecture and Q&A about "Ex-vivo cellular activation assays in the diagnosis and monitoring of food allergy - online event, 21/09/2020 |
| Year(s) Of Engagement Activity | 2020 |
| Description | International News coverage |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Our article entitled "Predicting progression to Alzheimer's disease with human hippocampal progenitors exposed to serum" by Maruszak et al. doi: 10.1093/brain/awac472 was covered -so far- by 236 news stories, with many interviews. Summary in the link below via Altmetric |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.altmetric.com/details/141831603/news |
| Description | News article |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | News article reporting on our paper: https://www.nature.com/articles/s42003-020-0844-1 |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.newscientist.com/article/2239489-diet-and-exercise-will-keep-your-brain-young-depending-... |
| Description | Talk for FARE and iFAAA |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A group of experts, industry partners and patient organisation leads and individual patients got together in a one day event which consisted of presentations and Q&A sessions about food allergy and anaphylaxis. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Virtual Food Allergy Fund Summit 2020 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Online Lecture "New approaches to the diagnosis of peanut allergy" at the Virtual Food Allergy Fund Summit 2020, 14th May 2020 |
| Year(s) Of Engagement Activity | 2020 |